Janssen Archives

genmab janssen blood cancer multiple myeloma

News and Trends 11 Jun 2019

Janssen and Genmab Team Up Again for Another Potential Cancer Blockbuster

Janssen and the Danish biotech Genmab will collaborate to develop a new antibody that could outperform their blockbuster cancer drug Darzalex in certain types of blood cancer. Genmab will develop the antibody treatment until it completes clinical proof-of-concept studies in the blood cancers multiple myeloma and diffuse large B-cell lymphoma. At that point, Janssen will […]

June 11, 2019 - 2 minutesmins - By Jonathan Smith

morphosys genmab janssen cancer immunotherapy

News and Trends 28 Jan 2019

Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents

Update (01/02/2019): MorphoSys has agreed to end its long-running legal battle with Genmab and Janssen, after the US District Court of Delaware declared three of its cancer immunotherapy patents invalid. MorphoSys began the dispute over Darzalex (daratumumab), Genmab and Janssen’s approved antibody therapy for the blood cancer multiple myeloma. MorphoSys alleged that Darzalex infringed on three of […]

January 28, 2019 - 3 minutesmins - By Dani Bancroft

Philogen cancer immunotherapy antibody pharma t cell

News and Trends 25 Jan 2019

Swiss-Italian Biotech Bags Antibody Deals with Three Big Pharma

The Swiss-Italian company Philogen has announced three different partnerships with Novartis, Celgene, and Janssen to develop new forms of immunotherapy and small molecule drugs. Philogen develops immunocytokines, which are antibodies that are fused with proteins that modify the immune system to fight diseases such as cancer. For example, this treatment can bind to tumors and activate […]

January 25, 2019 - 2 minutesmins - By Jonathan Smith

janssen microbiome inflammatory bowel disease

News and Trends 13 Dec 2018

Janssen Recruits Microbiome Company to Fight Inflammatory Bowel Disease

The Israeli biotech BiomX has teamed up with Janssen to use its microbiome technology in the treatment of inflammatory bowel diseases such as Crohn’s disease. Janssen aims to use BiomX’s technology to predict which patients with inflammatory bowel diseases will respond best its treatments based on their microbiome. The financial details of the collaboration were […]

December 13, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 1 Nov 2018

Llama Antibodies Could Be the Key to Universal Flu Prevention

Researchers have developed a new approach to prevent the flu that can protect against all seasonal strains of the virus. It also has potential to be effective for those that cannot get vaccinated. In a paper published in Science today, researchers at Janssen and The Scripps Research Institute have revealed a new approach to prevent […]

November 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Jul 2018

A New HIV Vaccine Could Protect Patients Against Multiple Viral Strains

A new HIV vaccine is moving into a Phase IIb trial and could potentially protect patients against multiple HIV strains worldwide. Recent findings from a Phase I/IIa trial published in The Lancet show that a new HIV-1 vaccine was safe and produced an immune response against HIV 393 healthy adults, as well as in a […]

July 6, 2018 - 2 minutesmins - By Alexander Burik

janssen biotech theravance bowel inflammation

News and Trends 8 Feb 2018

Janssen Biotech Offers up to $1Bn to Irish Biotech for a Bowel Inflammation Drug

Janssen Biotech and Theravance Biopharma will develop together a drug to treat bowel inflammation diseases like ulcerative colitis and Crohn’s disease. Janssen Biotech has set its eyes on a drug candidate being developed by the Irish Theravance Biopharma. Both have entered an agreement to co-develop and commercialize the drug. In exchange, Theravance is getting $100M (€82M) […]

February 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

hypertension treatment idorsia janssen2 1

News and Trends 4 Dec 2017

Swiss Biotech Brings in Reinforcements to See Hypertension Drug Through Phase III

Idorsia will collaborate with Janssen on the development of its hypertension drug, aprocitentan, which could help to prevent future heart attacks and strokes. Idorsia was born out of Actelion’s massive $30B (€27.9B) acquisition by Johnson & Johnson, retaining all of the former biotech’s early-stage assets. The company develops small molecules for a broad range of […]

December 4, 2017 - 3 minutesmins - By Alex Dale

News and Trends 27 Sep 2017

Belgian Pharma’s Single-Tablet HIV Treatment Approved in the EU

Janssen’s single-tablet regimen, Symtuza, has been approved by the European Commission for the treatment of HIV in adults and adolescents in the EU. The pharmaceutical arm of Johnson & Johnson, Janssen, has announced that the European Commission has approved its single-tablet regimen (STR), Symtuza, to treat Human Immunodeficiency Virus (HIV) infections. Previous studies have demonstrated […]

September 27, 2017 - 3 minutesmins - By Alex Dale

Morphosys Janssen Guselkumab approval psoriasis

News and Trends 18 Sep 2017

Update: After 25 years, MorphoSys Gets its First Antibody Approved

Update (19/09/2017): Janssen has received a positive CHMP opinion recommending the approval of Tremfya (guselkumab) in Europe for moderate to severe plaque psoriasis. The approval could make Tremfya the first antibody developed by MorphoSys to hit the European market, just a few months after its US approval. Originally published on 14/07/2017 Janssen has received FDA approval for Tremfya […]

September 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Jun 2017

What Cancer Therapies did European Biotechs Showcase at ASCO 2017?

Here are the most innovative therapies presented by European biotechs fighting cancer during the ASCO 2017 meeting in Chicago. European biotech was in the spotlight during this year’s edition of the American Society of Clinical Oncology (ASCO) meeting, with impressive results from some of the most novel approaches under development to fight multiple forms of cancer. From a […]

June 7, 2017 - 5 minutesmins - By Clara Rodríguez Fernández

More News! 9 Feb 2017

After its First Success, the Virtual Biotech Team is Back at it Again

SuperX has raised €10.3M ($11M) in Series A from Medicxi and J&J Innovation to develop anticoagulant antibodies for stroke and heart attacks. The team behind XO1, which was acquired by J&J’s Janssen back in 2015, is repeating the whole process again. Their new company, SuperX, is also focused on the discovery of anticoagulant antibodies to treat […]

February 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Janssen

Janssen and Genmab Team Up Again for Another Potential Cancer Blockbuster

Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents

Swiss-Italian Biotech Bags Antibody Deals with Three Big Pharma

Janssen Recruits Microbiome Company to Fight Inflammatory Bowel Disease

Llama Antibodies Could Be the Key to Universal Flu Prevention

A New HIV Vaccine Could Protect Patients Against Multiple Viral Strains

Janssen Biotech Offers up to $1Bn to Irish Biotech for a Bowel Inflammation Drug

Swiss Biotech Brings in Reinforcements to See Hypertension Drug Through Phase III

Belgian Pharma’s Single-Tablet HIV Treatment Approved in the EU

Update: After 25 years, MorphoSys Gets its First Antibody Approved

What Cancer Therapies did European Biotechs Showcase at ASCO 2017?

After its First Success, the Virtual Biotech Team is Back at it Again

Subscribe to our newsletter to get the latest biotech news!

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!